KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients

American Journal of Kidney Diseases

Volumn 56, Issue 2, 2010, Pages 189-218

  Bia, Margaret ^a   Adey, Deborah B ^b   Bloom, Roy D ^c   Chan, Laurence ^d   Kulkarni, Sanjay ^a   Tomlanovich, Steven ^e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

calcineurin inhibitor (CNI); inhibitor of mammalian target of rapamycin (mTOR inhibitor); KDIGO; KDOQI; Kidney transplant recipients (KTRs); mycophenolate compound (MPA compound)

Indexed keywords

ACICLOVIR; ADEFOVIR; ALEMTUZUMAB; ANTIBIOTIC AGENT; ATOVAQUONE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHICKENPOX VACCINE; COTRIMOXAZOLE; CYCLOSPORIN A; DACLIZUMAB; ENTECAVIR; EVEROLIMUS; FAMCICLOVIR; GANCICLOVIR; HEPATITIS B VACCINE; IMMUNOGLOBULIN; INFLUENZA VACCINE; LAMIVUDINE; LIVE VACCINE; MYCOPHENOLIC ACID; OKT 3; PENTAMIDINE; PREDNISONE; RAPAMYCIN; TACROLIMUS; TENOFOVIR; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VALGANCICLOVIR; CREATININE; GLUCOCORTICOID;

ACUTE GRAFT REJECTION; BIOLOGICAL MONITORING; CANCER SCREENING; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; COUNSELING; CYTOMEGALOVIRUS; DELAYED GRAFT FUNCTION; DRUG MEGADOSE; DYSLIPIDEMIA; EPSTEIN BARR VIRUS; GLOMERULUS FILTRATION RATE; GRAFT INFECTION; GRAFT RECIPIENT; HEALTH CARE POLICY; HEMOLYTIC UREMIC SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; LIP CANCER; LOW DRUG DOSE; MEDICAL DECISION MAKING; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MONOTHERAPY; NOTE; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; POLYOMA VIRUS; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PYELONEPHRITIS; SIDE EFFECT; SKIN CANCER; STEROID THERAPY; SURGEON; TERATOGENICITY; TESTOSTERONE BLOOD LEVEL; TUBERCULOSIS; UNITED STATES; URINARY TRACT INFECTION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VITAMIN D DEFICIENCY; ALLOTRANSPLANTATION; ARTICLE; BLOOD; CLINICAL PROTOCOL; IMMUNOCOMPROMISED PATIENT; LIFESTYLE; LIP TUMOR; MONITORING; NEOPLASM; POSTOPERATIVE CARE; SKIN TUMOR; STANDARD;

CLINICAL PROTOCOLS; CREATININE; GLOMERULAR FILTRATION RATE; GLUCOCORTICOIDS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LIFE STYLE; LIP NEOPLASMS; MONITORING, PHYSIOLOGIC; NEOPLASMS; POSTOPERATIVE CARE; PRACTICE GUIDELINES AS TOPIC; SKIN NEOPLASMS; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 77955854680     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2010.04.010     Document Type: Article

References (89)

1. K.P. McCullough, D.S. Keith, and K.H. Meyer, et al. Kidney and pancreas transplant in the United States, 1998-2007: access for patients with diabetes and end stage renal disease Am J Transplant 9 2009 894 906
2. G. Eknoyan, N. Lameire, and R. Barsoum, et al. The burden of kidney disease: improving global outcomes Kidney Int 66 2004 1310 1414
3. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO clinical practice guidelines for the care of kidney transplant recipients Am J Transplant 9 suppl 3 2009 S19 S20
4. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO clinical practice guideline for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease Kidney Int Suppl 109 2008 S1 S99
5. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int Suppl 113 2009 S1 S113
6. K.A. Andreoni, K.L. Brayman, M.K. Guidinger, C.M. Sommers, and R.S. Sung Kidney and pancreas transplantation in the United States, 1996-2005 Am J Transplant 7 2007 1359 1375
7. H. Ekberg, H. Tedesco-Silva, and A. Demirbas, et al. Reduced exposure to calcineurin inhibitors in renal transplantation N Engl J Med 357 2007 2562 2575
8. H. Ekberg, C. Bernasconi, and H. Tedesco-Silva, et al. Calcineurin inhibitor minimization in the Symphony Study: observational results 3 years after transplantation Am J Transplant 9 2009 1876 1885
9. O.I. Egbuna, R. Davis, and R. Chudinski, et al. Outcomes with conversion from calcineurin inhibitors to sirolimus after renal transplantation in the context of steroid withdrawal or steroid continuation Transplantation 88 2009 684 692
10. Y. Lebranchu, A. Thierry, and O. Toupance, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study Am J Transplant 5 2009 1115 1123
11. J.D. Schold, and B. Kaplan AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients Am J Transplant 9 2009 2067 2074
12. R.S. Gaston, B. Kaplan, and T. Shah, et al. Fixed or controlled-dose mycophenolate mofetil with standard or reduced-dose calcineurin inhibitors: the Opticept trial Am J Transplant 9 2009 1607 1619
13. D. Rush, D. Arlen, and A. Boucher, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study Am J Transplant 7 2007 2538 2545
14. A.T. Chang, and J.C. Platt The role of antibodies in transplantation Transpl Rev 23 2009 191 198
15. M. Abbud-Filho, P.L. Adams, and J. Alberú, et al. A report of the Lisbon Conference on the care of the kidney transplant recipient Transplantation 83 8 suppl 2007 S1 S22
16. A.K. Israni, J.J. Snyder, M.A. Skeans, A.V. Tuomari, J.R. Maclean, and B.L. Kasiske Who is caring for kidney transplant patients? Variation by region, transplant center, and patient characteristics Am J Nephrol 30 5 2009 430 439
17. P.C. Lee, L. Zhu, P. Terasaki, and M.J. Everly HLA specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss Transplantation 88 2009 568 574
18. M.J. Everly, and P.I. Terasaki Monitoring and treating posttransplant human leukocyte antigen antibodies Hum Immunol 70 2009 655 659
19. L.M. Birnbaum, M. Lipman, and S. Paraskevas, et al. Management of chronic allograft nephropathy: a systematic review Clin J Am Soc Nephrol 4 2009 860 865
20. A.S. Levey, K.-U. Eckardt, and T. Tsukamoto, et al. Definition and classification of Chronic Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int 67 2005 2089 2100
21. S. Jiménez Alvaro, R. Marcén, and J.L. Teruel, et al. Management of chronic kidney disease after renal transplantation: is it different from nontransplant patients? Transplant Proc 41 2009 2409 2411
22. F.J. Burgos, J. Pascual, and R. Marcen, et al. The role of imaging techniques in renal transplantation World J Urol 22 2004 399 404
23. O. Hergesell, H. Felten, and K. Andrassy, et al. Safety of ultrasound guided percutaneous renal biopsy - retrospective analysis of 1090 consecutive cases Nephrol Dial Transplant 13 1998 975 977
24. M. Mengel, J.R. Chapman, and F.G. Cosio, et al. Protocol biopsies in renal transplantation: insights into patient management and pathogenesis Am J Transplant 7 2007 512 517
25. J. Reeve, G. Einecke, and M. Mangel : Diagnosing rejection in renal transplants: a comparison of molecular- and histolopathology-based approaches Am J Transplant 9 2009 1802 1810
26. S. Bunnag, G. Einecke, and J. Reeve, et al. Molecular correlates of renal function in kidney transplant biopsies J Am Soc Nephrol 20 2009 1149 1160
27. P. Saint-Mezard, C.C. Berthier, and H. Zhang, et al. Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection Transplant Int 3 2009 293 302
28. W.A. Golgert, G.B. Appel, and S. Hariharan Recurrent glomerulonephritis after renal transplantation: an unsolved problem Clin J Am Soc Nephrol 3 2008 800 807
29. G.M. Ghiggeri, M. Carraro, and F. Vincenti Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy Nephrol Dial Transplant 19 2004 1036 1040
30. B.Y. Choy, T.M. Chan, and K.N. Lai Recurrent glomerulonephritis after kidney transplantation Am J Transplant 6 2006 2535 2542
31. M.A. Little, P. Dupont, and E. Campbell, et al. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk Kidney Int 69 2006 504 511
32. R.N. Fine, Y. Becker, and S. De Geest, et al. Nonadherence consensus conference summary report Am J Transplant 9 2009 35 41
33. P.E. Morrissey, M.L. Flynn, and S. Lin Medication noncompliance and its implications in transplant recipients Drugs 67 2007 1463 1481
34. H. Vlaminck, B. Maes, and G. Evers, et al. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients Am J Transplant 4 2004 1509 1513
35. AST Infectious Diseases Guidelines 2nd Edition Am J Transplant 9 suppl 4 2009 S1 S281
36. E. Akalin, S. Ames, V. Sehgal, B. Murphy, and J. Bromberg Safety of using hepatitis B core antibody or surface antigen-positive donors in kidney or pancreas transplantation Clin Transplant 19 2005 364 366
37. A. Duchini, J. Goss, S. Karpen, and P. Pockros Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols Clin Microbiol Rev 16 3 2003 357 364
38. A randomized, placebo-controlled, dose-escalation study to assess the safety and effect of cidofivir in renal transplant recipients with BK virus nephropathy. NCT001384424. Clinical Trials.Gov. Accessed May 17, 2010.
39. A multicenter, randomized, double-blind, placebo-controlled, multiple dose study of the safety, tolerability and population pharmacokinetics of CMX001 in post-transplant patients with BK virus viuria. NCT00793598. ClinicalTrials.Gov. Accessed May 17, 2010
40. V. Kliem, L. Fricke, T. Wollbrink, M. Burg, J. Radermacher, and F. Rohde Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial Am J Transplant 8 5 2008 975 983
41. A. Weinberg, T.N. Hodges, and S. Li, et al. Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation J Clin Microbiol 38 2000 768 772
42. N.N. Zein, J. Rakela, E.L. Krawitt, K.R. Reddy, T. Tominaga, and D.H. Persing Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy Collaborative Study Group Ann Intern Med 125 8 1996 634 639
43. M.E. Roland, B. Barin, and L. Carlson, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes Am J Transplant 8 2008 355 365
44. L. Richeldi, M. Losi, and R. D'Amico, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients Chest 136 1 2009 198 204
45. Y. Kobashi, K. Mouri, and Y. Obase, et al. Clinical evaluation of Quantiferon TB-2G test for immunocompromised patients Eur Respir J 30 2007 945 950
46. B.L. Kasiske, J.J. Snyder, D. Gilbertson, and A.J. Matas Diabetes mellitus after kidney transplantation in the United States Am J Transplant 3 2003 178 185
47. R.S. Woodward, M.A. Schnitzler, and J. Baty, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients Am J Transplant 3 2003 590 598
48. J.H. Nam, J.I. Mun, and S.I. Kim, et al. Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus Transplantation 71 2001 1417 1423
49. B. Isomaa, P. Almgren, and T. Tuomi, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome Diabetes Care 24 2001 683 689
50. A.P. de Vries, S.J. Bakker, and W.J. van Son, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally Am J Transplant 4 2004 1675 1683
51. F.G. Cosio, Y. Kudva, and M. van der Velde, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation Kidney Int 67 2005 2415 2421
52. K.A. Armstrong, J.B. Prins, and E.M. Beller, et al. Should an oral glucose tolerance test be performed routinely in all renal transplant recipients? Clin J Am Soc Nephrol 1 2006 100 108
53. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 208;358:2545-2559.
54. A. Patel, S. MacMahon, and J. Chalmers, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2560 2572
55. National Kidney Foundation KDOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease Am J Kidney Dis 43 suppl 1 2004 S1 S290
56. A.V. Chobanian, G.L. Bakris, and H.R. Black, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572
57. G. Heinze, C. Mitterbauer, and H. Regele, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation J Am Soc Nephrol 17 2006 889 899
58. G. Opelz, M. Zeier, G. Laux, C. Morath, and B. Dohler No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report J Am Soc Nephrol 17 2006 3257 3262
59. J.M. Arthur, and S. Shamim Interaction of cyclosporine and FK506 with diuretics in transplant patients Kidney Int 58 2000 325 330
60. B. Kasiske, F.G. Cosio, and J. Beto, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative Am J Transplant 4 2004 13 53
61. W.P. Lemahieu, M. Hermann, and A. Asberg, et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus Am J Transplant 5 2005 2236 2243
62. E.S. Woodle, M.R. First, J. Pirsch, F. Shihab, A.O. Gaber, and P. Van Veldhuisen A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy Ann Surg 248 2008 564 577
63. R.N. Foley, P.S. Parfrey, and M.J. Sarnak Clinical epidemiology of cardiovascular disease in chronic renal disease Am J Kidney Dis 32 suppl 3 1998 S112 S119
64. H.U. Meier-Kriesche, R. Baliga, and B. Kaplan Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation Transplantation 75 2003 1291 1295
65. R.S. Gaston, B.L. Kasiske, and A.M. Fieberg, et al. Use of cardioprotective medications in kidney transplant recipients Am J Transplant 9 2009 1811 1815
66. C. Ulrich, H.S. Jurgensen, and A. Degen, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of sunscreen: a 24 months, prospective, case-control study Br J Dermatol 161 suppl 3 2009 78 84
67. E. Mahe, E. Morelon, and J. Fermanian, et al. Renal-transplant recipients and sun protection Transplantation 78 2004 741 744
68. F. Ismail, D. Mitchell, and A. Casabone, et al. Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photo protection and levels of skin cancer awareness Br J Dermatol 155 5 2008 916 925
69. J.M. Campistol, J. Eris, and R. Oberbauer, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation J Am Soc Nephrol 17 2006 581 589
70. N. Chalasani, A. Said, and R. Ness, et al. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey Am J Gastroenterol 94 1999 2224 2229
71. A.E. Grulich, M.T. van Leeuwen, and M.O. Falster, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis Lancet 370 2007 59 67
72. G. Stallone, B. Infante, and P. Pontrelli, et al. ID2-VEGF-related pathways in the pathogenesis of Kaposi's sarcoma: a link disrupted by rapamycin Am J Transplant 9 3 2009 558 586
73. S. Duman, H. Toz, and G. Asci, et al. Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression Nephrol Dial Transplant 17 2002 892 896
74. E. Rojas, R. Carlini, and P. Clesca, et al. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling Kidney Int 63 2003 1915 1923
75. A. Stavroulopoulos, M.J.D. Cassidy, C.J. Porter, D.J. Hosking, and S.D. Roe Vitamin D status in renal transplant patients Am J Transplant 7 2007 2546 2552
76. S.C. Palmer, G. Strippoli, and D. McGregor Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials Am J Kidney Dis 45 2005 638 649
77. M. Coco, D. Glicklich, and M.C. Fuagere, et al. Prevention of bone loss in renal transplant recipients: a prospective randomized trial of intravenous pamidronate J Am Soc Nephrol 14 2003 2669 2676
78. C.K.T. Farmer, G. Hampson, and I.C. Abbs Late low-dose steroid withdrawal in renal transplant recipients increases bone formation and bone mineral density Am J Transplant 6 2006 2929 2936
79. E. van den Ham, J.P. Kooman, and C.M.J.P. van Hoof The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients Transplant Int 16 2003 82 87
80. U. Nisbeth, E. Lindh, S. Ljunghall, U. Backman, and B. Fellstrom Increased fracture rate in diabetics and females after renal transplantation Transplantation 67 1999 1218 1222
81. R. Ramsey-Goldman, J.E. Dunn, and D.D. Dunlop, et al. Increased risk of fracture in patients receiving solid organ transplants J Bone Miner Res 14 1999 456 463
82. S.J. Chadban, L. Baines, and K. Polkinghorne, et al. Anemia after kidney transplantation is not completely explained by reduced kidney function Am J Kidney Dis 49 2007 301 309
83. National Kidney Foundation KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease Am J Kidney Dis 47 suppl 3 2006 S1 S146
84. D. Vimalachandra, J.C. Craig, and C.T. Cowell, et al. Growth hormone treatment in children with chronic renal failure: a meta-analysis of randomized controlled trials J Pediatr 39 2001 560 567
85. A. Tsujimura, K. Matsumiya, and N. Tsuboniwa, et al. Effect of renal transplantation on sexual function Arch Androl 48 2002 467 474
86. L. Raiz, E.A. Davies, and R.M. Ferguson Sexual functioning following renal transplantation Health Soc Work 28 2003 264 272
87. D.B. McKay, M.A. Josephson, and V.T. Armenti, et al. Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation Am J Transplant 5 2005 1592 1599
88. GLOBOCAN 2002 2002 International Agency for Research on Cancer, Cancer Mondial
89. United States Cancer Statistics: 1999-2005 incidence and mortality web-based report U.S. Cancer Statistics Working Group, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute (vol 2009) 2009 U.S. Cancer Statistics Working Group, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute Atlanta, GA